drugset / Trial / NCT05635591
KSD-101 Therapy for EBV-associated Haematologic Neoplasms: an Exploratory Clinical Trial
NaSingle-groupOpen-labelTreatment
Summary
The primary objectives of this study is to evaluate the tolerability and safety of KSD-101 in Patients with EBV-associated haematologic neoplasms, observe the dose-limiting toxicity (DLT) and and to explore the maximum tolerated dose (MTD).
Timeline
- Start
- 2023-01-16
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KSD-101 | Cell therapy | 5e+06 cells | Subcutaneous |
| Subject | KSD-101 | Cell therapy | 1e+07 cells | Subcutaneous |